Lanfredini, S.; Thapa, A. RAS in pancreatic cancer. Biochem. Soc. Trans., 2019, 47(4), 961-972.
Zeng, C.; Zhang, Z.; Wang, J. Application of the high-throughput TAB-array for the discovery of novel 5-hydroxymethylcytosine biomarkers in pancreatic ductal adenocarcinoma. Epigenomes, 2019, 3(3), 16.
Tan, Y.N.; Cao, K.N.; Ren, G.H. Effects of the ABCB1 and ABCG2 polymorphisms on the pharmacokinetics of afatinib in healthy Chinese volunteers. Xenobiotica, 2020, 50(2), 237-243.
Li, J.; Zhuang, C.; Liu, Y. Synthetic tetracycline-controllable shRNA targeting long non-coding RNA HOXD-AS1 inhibits the progression of bladder cancer. J. Experim. Clin. Cancer Res.: CR, 2016, 35(1), 99.
Huang, H.; Zepp, M.; Georges, R.B. The CCR5 antagonist maraviroc causes remission of pancreatic cancer liver metastasis in nude rats based on cell cycle inhibition and apoptosis induction. Cancer Lett., 2020, 474, 2-93.
Wang, K.; Zhan, Y.; Huynh, N. Inhibition of PAK1 suppresses pancreatic cancer by stimulation of anti-tumour immunity through down-regulation of PD-L1. Cancer Lett., 2020, 472, 8-18.
Yue, Y.; Qian, W.; Li, J. 2′-Hydroxyflavanone inhibits the progression of pancreatic cancer cells and sensitizes the chemosensitivity of EGFR inhibitors via repressing STAT3 signaling. Cancer Lett., 2020, 471, 135-146.
Caputo, D. Nanoparticle-enabled blood tests for early detection of pancreatic ductal adenocarcinoma. Cancer Lett., 2020, 470, 191-196.
Choi, E.A.; Choi, Y.S.; Lee, E.J. A pharmacogenomic analysis using L1000CDS identifies BX-795 as a potential anticancer drug for primary pancreatic ductal adenocarcinoma cells. Cancer Lett., 2019, 465, 82.
Quan, M.Y.; Guo, Q.; Liu, J.; Yang, R.; Bai, J.; Wang, W.; Cai, Y.; Han, R.; Lv, Y-Q.; Ding, L.; Billadeau, D.D.; Lou, Z.; Bellusci, S.; Li, X.; Zhang, J-S. An FGFR/AKT/SOX2 signaling axis controls pancreatic cancer stemness. Front. Cell Dev. Biol., 2020, 8, 287.
Pu, N.; Gao, S.; Yin, H. Cell-intrinsic PD-1 promotes proliferation in pancreatic cancer by targeting CYR61/CTGF via the hippo pathway. Cancer Lett., 2019, 460, 42-53.
Awasthi, N.; Kronenberger, D.; Stefaniak, A. Dual inhibition of the PI3K and MAPK pathways enhances nab-paclitaxel/gemcitabine chemotherapy response in preclinical models of pancreatic cancer. Cancer Lett., 2019, 459, 41-49.
Wang, H.; Jia, R.; Zhao, T. HIF-1α mediates tumor-nerve interactions through the up-regulation of GM-CSF in pancreatic ductal adenocarcinoma. Cancer Lett., 2019, 453, 10-20.
Wei, T.; Zhang, X.; Zhang, Q. Vimentin-positive circulating tumor cells as a biomarker for diagnosis and treatment monitoring in patients with pancreatic cancer. Cancer Lett., 2019, 452, 237.
Vendrely, V.; Amintas, S.; Noel, C. Combination treatment of resveratrol and capsaicin radiosensitizes pancreatic tumor cells by unbalancing DNA repair response to radiotherapy towards cell death. Cancer Lett., 2019, 451, 1-10.
Kumar, D.; Sarma, P.; Bhadra, M.P. Impact of The hybrid-polar histone deacetylase inhibitor m-carboxycinnamic acid bis-hydroxamide on human pancreatic adenocarcinoma cells. Anticancer. Agents Med. Chem., 2019, 19(6), 750-759.